Colorectal Cancer News

Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.

Aug

19

Oxford Journals: Fecal DNA Methylation Detects Gastric And Colorectal Cancers

A preliminary evaluation of methylation of two gene promoters in fecal DNA showed promise as a noninvasive method to detect colorectal and gastric cancers, according to a new study published online August 21 in the Journal of the National Cancer Institute.

Aug

17

Vectibix Significantly Improved Progression-Free Survival In Second-line Treatment Of KRAS Wild-Type Metastatic Colorectal Cancer

Amgen today announced positive top-line results from a Phase 3 trial evaluating Vectibix((R) ) (panitumumab) in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients with metastatic colorectal cancer (mCRC). The co-primary endpoints, tested independently, were progression-free and overall survival.

Aug

13

Aspirin Cuts Colon Cancer Death Risk

U.S. researchers say colon cancer patients taking aspirin could lower the risk of dying from the disease. Previous studies have already shown that aspirin reduces the risk of developing colon cancer. But a study in the Journal of the American Medical Association released Wednesday shows aspirin can also prevent colorectal cancer deaths in patients already diagnosed with the disease.

Aug

13

Exiqon Diagnostics Launches New ArQive Patient Registry For Colon, Lung And Ovarian Cancer

Exiqon announced the nationwide launch of the ArQive Registry, a prospective, observational study designed to strengthen the supporting data for the Oncotech Extreme Drug Resistance (EDR) Assay and to collect data to help develop novel molecular assays (miRNA) within three key tumor types: colon, lung and ovarian.

Aug

13

Vectibix In Combination With Chemotherapy Significantly Improved Progression-free Survival In First-Line Metastatic Colorectal Cancer

Amgen announced that Vectibix (panitumumab), administered in combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with FOLFOX alone in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC).

Aug

13

ARUP Laboratories Applauds FDA's Decision On The Value Of KRAS-mutation Testing In Colorectal Cancer

ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, supports the U.S. Food and Drug Administration's (FDA) decision to put KRAS on the label of two targeted drugs, Vectibix (panitumumab) and Erbitux (cetuximab).

Aug

13

Aspirin Is Seen To Improve Colon Cancer Survival Rate

It has long been known that people who take aspirin regularly are less likely to develop tumors of the colon, and now a study has found that even after a diagnosis of colorectal cancer, patients who take aspirin have a much better chance of surviving than non-users.

Aug

10

Cities Go Blue for Colon Cancer: New National Awareness Campaign Launched

The Colon Cancer Alliance (CCA) today announced the launch of its national awareness campaign, Cities Go Blue for Colon Cancer. Philadelphia, PA has been selected as the inaugural host city with events kicking off on September 26-27, 2009.

Aug

05

Cost-Effectiveness Of Cetuximab In Metastatic Colorectal Cancer

From a health-care system perspective, it may be more efficient to use the drug cetuximab only in colorectal cancer patients whose tumors have a wild-type KRAS gene, according to a study published online August 7 in the Journal of the National Cancer Institute.

Aug

04

Heavy Drinkers Face Increased Cancer Risk

Canadian researchers linked heavy consumption of beer and spirits to several cancers including esophageal, colon and lung cancers.

Page(s): Prev 12...4 5 6 7 8 9 10 ...178179 Next 

We care about your feedback. Let us know how we can improve your CancerCompass experience.